Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes
Rev. Assoc. Med. Bras. (1992, Impr.)
; 66(9): 1283-1288, Sept. 2020. tab, graf
Article
in English
| Sec. Est. Saúde SP, LILACS
| ID: biblio-1136379
Responsible library:
BR1.1
ABSTRACT
SUMMARY The pharmacological therapy for type 2 diabetes mellitus has presented important advances in recent years, which has impacted the treatment of patients with established cardiovascular disease or with high cardiovascular risk. In this scenario, two drug classes have emerged and demonstrated clear clinical benefits SGLT-2 inhibitors and GLP-1 agonists. The present review discusses the pharmacology, adverse effects, and clinical trials that have demonstrated the benefits of these medications in reducing cardiovascular risk.
RESUMO
RESUMO A terapia farmacológica do diabetes mellitus tipo 2 apresentou avanços importantes nos últimos anos, impactando principalmente o tratamento dos pacientes com doença cardiovascular estabelecida ou com alto risco cardiovascular. Nesse cenário, surgiram duas classes de fármacos com claros benefícios clínicos; os inibidores da SGLT-2 e os agonistas do GLP-1. Na presente revisão os autores discutem desde a farmacologia, efeitos adversos e também os estudos clínicos que demonstraram os benefícios dessas medicações na redução de risco cardiovascular.
Full text:
Available
Collection:
National databases
/
Brazil
Health context:
Sustainable Health Agenda for the Americas
/
SDG3 - Health and Well-Being
Health problem:
Goal 9: Noncommunicable diseases and mental health
/
Target 3.4: Reduce premature mortality due to noncommunicable diseases
Database:
LILACS
/
Sec. Est. Saúde SP
Main subject:
Cardiovascular Diseases
/
Diabetes Mellitus, Type 2
Type of study:
Etiology study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Rev. Assoc. Med. Bras. (1992, Impr.)
Year:
2020
Document type:
Article
Institution/Affiliation country:
USP/BR